PRF Technologies Ltd.
PRFXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. The $3.4M market capitalization puts PRFX squarely in micro-cap range for its industry. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Market Cap
$3.4M
Beta
1.04
P/E (TTM)
—
P/E (Fwd)
-0.08
EPS (TTM)
$-7.47
EPS (Fwd)
$-12.06
ROE
-90.4%
ROA
-38.8%
Cash
$4.1M
Total Debt
$21,000
Free CF
-$2.0M
52W Change
-86.3%
Annual Financials
Cash vs Debt
Where PRFX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PRFX finished 50.00% below its 150-day moving average ($1.94) and 61.81% below its 200-day moving average ($2.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRFX overbought or oversold?
At the September 3, 2026 close, PRFX's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
PRF Technologies Ltd. holds $4.1M in cash against $21K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$2.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -90.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRFX.